Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Cancer and Oncology›Dermatofibrosarcoma
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Dermatofibrosarcoma

Cancer and Oncology · NLM MeSH · updated 2026-10-29 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

A sarcoma of the deep layers of the skin.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (1,031 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A sarcoma of the deep layers of the skin. The tumors are locally aggressive tends to recur but rarely metastatic. It can be classified into variants depending on the cell type tumors are derived from or by its characteristics: Pigmented variant from melanin-containing dermal dendritic cells; Myxoid variant, myxoid stromal cells; Giant cell variant characterized by giant cells in the tumors; and Fibrosarcomatous variant chracterized by tumor areas histologically indistinguishable from fibrosarcoma.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Dermatofibrosarcomas; Darier-Ferrand Tumor; Darier Ferrand Tumor; Tumor, Darier-Ferrand; Darier-Hoffmann Tumor; Darier Hoffmann Tumor; Tumor, Darier-Hoffmann; Dermatofibrosarcoma Protuberan.

Where it fits in the MeSH classification

Broader topics
Fibrosarcoma

Related concepts

  • Melanin-
  • Langerhans Cells
  • Stromal Cells
  • Giant Cells
  • Fibrosarcoma

Research landscape

PubMed indexes 1,636 records tagged with the MeSH heading “Dermatofibrosarcoma” (counts retrieved 2026-10-29). 352 of them (21.5%) were published from 2020 onward, and the busiest period so far is 2010-2019 with 589 records.

Reviews account for 278 records (17.0%) and meta-analyses for 8. Randomized controlled trials number 0 (0.0%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 248 records; 2000-2009: 447 records; 2010-2019: 589 records; 2020 onward: 352 records248through 19994472000-20095892010-20193522020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 1999248
2000-2009447
2010-2019589
2020 onward352
Share of records by publication typeReviews: 17.0 percent; Meta-analyses: 0.5 percent; Randomized controlled trials: 0.0 percentReviews17.0% (278)Meta-analyses0.5% (8)Randomized controlled trials0.0% (0)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 1,636 PubMed records
TypeRecordsShare
Reviews27817.0%
Meta-analyses80.5%
Randomized controlled trials00.0%

Method: PubMed query "Dermatofibrosarcoma"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.

Reading the evidence in cancer and oncology

Cancer research spans very different kinds of evidence. Laboratory studies in cell lines and animal models reveal mechanisms but often do not translate to patients. Early-phase trials mainly test safety and dosing, while phase 3 randomized trials and their meta-analyses are the usual basis for treatment conclusions. Outcomes also differ in meaning: tumour shrinkage, progression-free survival and overall survival are not interchangeable, and screening studies can be distorted by lead-time and overdiagnosis. When reading a result, check the cancer type and stage studied, the comparison treatment, and which outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Dermatofibrosarcoma protuberans with fibrosarcomatous transformation of the head and neck
Angouridakis N, Kafas P, Jerjes W, Triaridis S, Upile T, Karkavelas G, et al.
2011Review article
Design not recorded in structured metadata
44cc by
PMID 21294902 · DOI · PMC3038985
Dermatofibrosarcoma protuberans treated by micrographic surgery
Ah-Weng A, Marsden JR, Sanders DS, Waters R
2002Review article
Design not recorded in structured metadata
43cc by
PMID 12454766 · DOI · PMC2376302
The efficacy of Mohs micrographic surgery over the traditional wide local excision surgery in the cure of dermatofibrosarcoma protuberans
Malan M, Xuejingzi W, Quan SJ
2019Meta-analysis
Design not recorded in structured metadata
38cc by
PMID 31692830 · DOI · PMC6815477
MRI-Based Surgical Margin Assessment in Dermatofibrosarcoma Protuberans: Correlation With Pathological Extent
Kito M, Iwaya M, Omodaka T, Yuzuriha S, Okamoto M, Tanaka A, et al.
2026Research article
Design not recorded in structured metadata
0cc by
PMID 42400167 · DOI · PMC13555155

Dermatofibrosarcoma protuberans with fibrosarcomatous transformation of the head and neck [1]

Review article Angouridakis N, Kafas P, Jerjes W, Triaridis S, Upile T, Karkavelas G, et al. · · 2011 · cited 44 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous neoplasm associated with a high cure rate.
Closing excerpt
Moreover, adjuvant treatment and follow-up of the patient is essential in order to prevent recurrence.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (119 words)

Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous neoplasm associated with a high cure rate. We present a case of aggressive DFSP with fibrosarcomatous areas in the head and neck. A 28-year-old Mediterranean female presented with a 45-day history of rapidly growing cutaneous lesion of the face. Surgical biopsy confirmed the diagnosis of DFSP. Subsequently, the patient underwent wide local surgical resection, followed by reconstruction. Histopathology report revealed fibrosarcomatous transformation and the patient underwent adjuvant radiotherapy. The patient continues to be disease free at the 35-month follow-up.Although DFSP behave as non-aggressive malignancy, surgery with complete removal of the affected area is the intervention of choice. Moreover, adjuvant treatment and follow-up of the patient is essential in order to prevent recurrence.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 21294902 · DOI · PMC3038985

Dermatofibrosarcoma protuberans treated by micrographic surgery [2]

Review article Ah-Weng A, Marsden JR, Sanders DS, Waters R · · 2002 · cited 43 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Dermatofibrosarcoma protuberans is an uncommon cutaneous tumour which rarely metastasises.
Closing excerpt
The study provides further support for micrographic surgery as the treatment of choice for dermatofibrosarcoma protuberans.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (188 words)

Dermatofibrosarcoma protuberans is an uncommon cutaneous tumour which rarely metastasises. However, local recurrence following apparently adequate surgical excision is well recognised, presumably as a result of sub-clinical contiguous growth, for which micrographically controlled excision would be a logical treatment. A retrospective study of all patients treated by micrographic surgery, from April 1995-March 2000, at a tertiary skin oncology centre. Twenty-one patients (11 males), age 14 to 71 years with dermatofibrosarcoma protuberans on the trunk (10 patients), groin (four), head and neck (four), and limbs (three) were treated. In 15 patients one micrographic layer cleared the tumour, and four were cleared with two layers. For one patient the second stage was completed by conventional excision guided by positive margins. Another patient with a multiply recurrent perineal dermatofibrosarcoma protuberans, not cleared in one area after two layers, died from a pulmonary embolus before total clearance could be achieved. There was no correlation between tumour size and lateral excision margin. No recurrence was observed during the follow-up, from 21 to 80 months, median 47 months. The study provides further support for micrographic surgery as the treatment of choice for dermatofibrosarcoma protuberans.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 12454766 · DOI · PMC2376302

The efficacy of Mohs micrographic surgery over the traditional wide local excision surgery in the cure of dermatofibrosarcoma protuberans [3]

Meta-analysis Malan M, Xuejingzi W, Quan SJ · · 2019 · cited 38 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Usually most patients with dermatofibrosarcoma protuberans (DFSP) may present rather late when the tumor is in protuberant phase due to its rarity and indolent onset.
Closing excerpt
Mohs Micrographic Surgery (MMS) is more efficacious in the cure rate and recurrence reduction of DFSP and should be advocated for as first line therapy especially in high recurrence prone zones.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (431 words)

Usually most patients with dermatofibrosarcoma protuberans (DFSP) may present rather late when the tumor is in protuberant phase due to its rarity and indolent onset. It has a high propensity for local recurrence and destructive nature. Management of DFSP requires a biopsychosocial and Multidisplinary approach regardless of the clinical or immunohistochemical variant. Surgery is the Gold standard management of localized disease. DFSP rarely exhibits any lymphatic or hematogenous dissemination. It is because of its high recurrence rate associated with Wide Local Excision (WLE), the introduction of Mohs micrographic surgery (MMS) has really helped in reducing the rates of recurrence of DFSP. Thus, the aim of this meta-analysis and systemic review is to advocate for MMS over WLE for DFSP and other cutaneous malignancies using DFSP as a prototype. The objective of this study were to conduct a meta-analysis on comparative surgical methods used in the cure of DFSP with regards to WLE verses MMS, to evaluate the cure rates with relation to recurrence rates, offer a recommendation on the various treatment modalities based on the location of lesion, and use of adjuvant therapy in different clinical-medical setups. A comprehensive retrospective analysis search in EMBASE, Google Scholar and Medline (PubMed) for studies published from 2008 to 2018 containing the surgical management of DFSP with WLE verses MMS were reviewed. Five studies of moderate-quality evidence (level B) with a pooled patient load of 684 was analyzed and found for recurrence of DFSP after WLE and MMS to be 9.10% and 2.72% respectively after an average follow-up time for both groups of 5.32 years with a female predominance of 1.58. The trunk is the commonest site for the DFSP lesion which was at 52.80% then the upper and lower extremities zones and the head and neck zones at 31.75% and 15.45% respectively. The pooled adjusted odds ratio (OR) analysis indicated that there was a direct relationship with regards the reduced recurrence rate of DFSP in the MMS group compared to the WLE group (OR:0.31;95%; CI :0.17-0.56). Furthermore, there was significant association between the reduced recurrence rate with the MMS in DFSP patients with a statistical P-value of 0.0001 at 95% CI. The expected increased recurrence rate by zones was in WLE head and neck zone at 38.19% then trunk and extremities zone at 13.34%. In the MMS group it was at of 23.4% as compared to 16.0% in the head and neck zone. Mohs Micrographic Surgery (MMS) is more efficacious in the cure rate and recurrence reduction of DFSP and should be advocated for as first line therapy especially in high recurrence prone zones.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 31692830 · DOI · PMC6815477

MRI-Based Surgical Margin Assessment in Dermatofibrosarcoma Protuberans: Correlation With Pathological Extent [4]

Research article Kito M, Iwaya M, Omodaka T, Yuzuriha S, Okamoto M, Tanaka A, et al. · · 2026

Abstract reading summary — source excerpts
Opening excerpt
Dermatofibrosarcoma protuberans (DFSP) is a locally aggressive cutaneous tumor characterized by infiltrative growth and a high risk of local recurrence if incompletely excised.
Closing excerpt
A lateral margin of approximately 20 mm appears sufficient to achieve complete resection, and fascia-based evaluation may help stratify the risk of deep invasion.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (293 words)

Dermatofibrosarcoma protuberans (DFSP) is a locally aggressive cutaneous tumor characterized by infiltrative growth and a high risk of local recurrence if incompletely excised. Although Mohs micrographic surgery is recommended, wide local excision (WLE) remains widely used in clinical practice; however, the clinical utility of preoperative imaging for surgical margin assessment has not been fully established. We retrospectively analyzed 42 patients with DFSP, including fibrosarcomatous DFSP (FS-DFSP), who underwent MRI-based surgical planning followed by WLE between 2009 and 2023. Lateral margins were defined based on preoperative MRI, and deep tumor extent was assessed according to the relationship with the fascia. Analyses were performed in 36 patients after excluding cases without identifiable pathological tumor. The median planned lateral margin was 20 mm, whereas the median pathological margin was 16.5 mm. The median difference (pathological - planned) was -5 mm (interquartile range -10.25 to -1 mm; range -18 to +15 mm), with planned margins significantly larger (p < 0.001). A weak positive correlation was observed between planned and pathological margins (ρ = 0.32), but it did not reach statistical significance (p = 0.060). Importantly, the maximum underestimation of tumor extent was 18 mm, indicating that the discrepancy between imaging-based planning and pathological findings did not exceed 20 mm in any case. Lesions classified as fascia-contacting or beyond on MRI showed a higher likelihood of deep invasion (OR 27.0, 95% CI 1.5-483). Residual tumor was identified in 71% of patients undergoing additional resection after unplanned excision. All patients achieved R0 resection without local recurrence, and distant metastases occurred only in FS-DFSP. Preoperative MRI provides clinically useful information for surgical margin assessment in DFSP. A lateral margin of approximately 20 mm appears sufficient to achieve complete resection, and fascia-based evaluation may help stratify the risk of deep invasion.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42400167 · DOI · PMC13555155

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Dermatofibrosarcoma protuberans [5]
    Gloster HM · J Am Acad Dermatol · 1996 · cited 233 times (Europe PMC)
  • Research article A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans [6]
    Gloster HM, Harris KR, Roenigk RK · J Am Acad Dermatol · 1996 · cited 199 times (Europe PMC)
  • Research article Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment [7]
    Sirvent N, Maire G, Pedeutour F · Genes Chromosomes Cancer · 2003 · cited 182 times (Europe PMC)
  • Research article Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management [8]
    Llombart B, Serra-Guillén C, Monteagudo C, López Guerrero JA, Sanmartín O · Semin Diagn Pathol · 2013 · cited 170 times (Europe PMC)
  • Research article Current treatment options in dermatofibrosarcoma protuberans [9]
    Lemm D, Mügge LO, Mentzel T, Höffken K · J Cancer Res Clin Oncol · 2009 · cited 165 times (Europe PMC)
  • Research article Dermatofibrosarcoma protuberans [10]
    Mendenhall WM, Zlotecki RA, Scarborough MT · Cancer · 2004 · cited 135 times (Europe PMC)

References

  1. Angouridakis N, Kafas P, Jerjes W, Triaridis S, Upile T, Karkavelas G, et al.. Dermatofibrosarcoma protuberans with fibrosarcomatous transformation of the head and neck. . 2011. PMID 21294902 · DOI · PMC3038985
  2. Ah-Weng A, Marsden JR, Sanders DS, Waters R. Dermatofibrosarcoma protuberans treated by micrographic surgery. . 2002. PMID 12454766 · DOI · PMC2376302
  3. Malan M, Xuejingzi W, Quan SJ. The efficacy of Mohs micrographic surgery over the traditional wide local excision surgery in the cure of dermatofibrosarcoma protuberans. . 2019. PMID 31692830 · DOI · PMC6815477
  4. Kito M, Iwaya M, Omodaka T, Yuzuriha S, Okamoto M, Tanaka A, et al.. MRI-Based Surgical Margin Assessment in Dermatofibrosarcoma Protuberans: Correlation With Pathological Extent. . 2026. PMID 42400167 · DOI · PMC13555155
  5. Gloster HM. Dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1996. PMID 8784271 · DOI
  6. Gloster HM, Harris KR, Roenigk RK. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1996. PMID 8682970 · DOI
  7. Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer. 2003. PMID 12661001 · DOI
  8. Llombart B, Serra-Guillén C, Monteagudo C, López Guerrero JA, Sanmartín O. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management. Semin Diagn Pathol. 2013. PMID 23327727 · DOI
  9. Lemm D, Mügge LO, Mentzel T, Höffken K. Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol. 2009. PMID 19205737 · DOI · PMC12160171
  10. Mendenhall WM, Zlotecki RA, Scarborough MT. Dermatofibrosarcoma protuberans. Cancer. 2004. PMID 15503305 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-29.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Giant Cell Tumor of BoneCancer and Oncology
  • Giant Cell TumorsCancer and Oncology
  • FibrosarcomaCancer and Oncology
  • Phyllodes TumorCancer and Oncology
  • Gastrointestinal Stromal TumorsCancer and Oncology
  • Granular Cell TumorCancer and Oncology

All 107 articles in Cancer and Oncology →

At a glance

1,636
PubMed records on this heading
22%
published since 2020
278
review articles
0
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-29; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Giant Cell Tumor of BoneCancer and Oncology
  • Giant Cell TumorsCancer and Oncology
  • FibrosarcomaCancer and Oncology
  • Phyllodes TumorCancer and Oncology
  • Gastrointestinal Stromal TumorsCancer and Oncology

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support